远程医疗服务公司Hims & Hers Health Inc.（HIMS）今日夜盘大幅上涨5.64%，引起了市场的广泛关注。
消息面上，该公司与丹麦制药巨头诺和诺德（Novo Nordisk）达成了一项重要的合作协议。根据协议，诺和诺德将通过Hims & Hers的平台销售其明星减肥药物Wegovy和Ozempic，这标志着双方从法律纠纷转向商业合作。
作为协议的一部分，诺和诺德同意撤回此前对Hims & Hers提起的专利侵权诉讼。同时，Hims & Hers承诺将停止宣传其仿制的GLP-1减肥药物，仅在医生认为有临床必要时才提供复合制剂。美国食品药品监督管理局（FDA）官员对此合作表示赞赏，认为这将有助于保障患者用药安全。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.